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Purpose: Cognitive impairment in cancer patients induced, at least in part, by treatment
are frequently observed and likely have negative impacts on patient quality of life.
Such cognitive dysfunctions can affect attention, executive functions, and memory and
processing speed, can persist after treatment, and their exact causes remain unclear.
The aim of this review was to create an inventory and analysis of clinical studies
evaluating biological markers and risk factors for cognitive decline in cancer patients
before, during, or after therapy. The ultimate objectives were to identify robust markers
and to determine what further research is required to develop original biological markers
to enable prevention or adapted treatment management of patients at risk.
Method: This review was guided by the PRISMA statement and included a
search strategy focused on three components: “cognition disorders,” “predictive
factors”/“biological markers,” and “neoplasms,” searched in PubMed since 2005, with
exclusion criteria concerning brain tumors, brain therapy, and imaging or animal studies.
Results: Twenty-three studies meeting the criteria were analyzed. Potential
associations/correlations were identified between cognitive impairments and specific
circulating factors, cerebral spinal fluid constituents, and genetic polymorphisms at
baseline, during, and at the end of treatment in cancer populations. The most significant
results were associations between cognitive dysfunctions and genetic polymorphisms,
including APOE-4 and COMT-Val; increased plasma levels of the pro-inflammatory
cytokine, IL-6; anemia; and hemoglobin levels during chemotherapy. Plasma levels
of specific hormones of the hypothalamo-pituitary-adrenal axis are also modified by
treatment.
Discussion: It is recognized in the field of cancer cognition that cancer
and comorbidities, as well as chemotherapy and hormone therapy, can cause
persistent cognitive dysfunction. A number of biological circulating factors and genetic
polymorphisms, can predispose to the development of cognitive disorders. However,
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many predictive factors remain unproven and discordant findings are frequently reported,
warranting additional clinical and preclinical longitudinal cohort studies, with goals of
better characterization of potential biomarkers and identification of patient populations
at risk and/or particularly deleterious treatments. Research should focus on prevention
and personalized cancer management, to improve the daily lives, autonomy, and return
to work of patients.
Keywords: cognitive disorders, biological markers, predictive factors, cancer, chemotherapy
INTRODUCTION
There have been improvements in the efficacy of cancer
treatments, and also in the management of side effects and
patient care over the last decade. However, cancer treatments,
most often chemotherapy, may induce side effects on the bone
marrow, heart, cardiac, or digestive system and often cause
nausea, alopecia, or even cognitive impairments Ahles (2012).
Chemotherapy can cross the blood brain barrier (BBB) and cause
brain damage (Cheung et al., 2015; Wang et al., 2015), which
could explain cognitive impairments, including of concentration,
memory, executive functions, and processing speed, symptoms
often referred to as “chemofog” or “chemobrain” (Vardy et al.,
2008; Joly et al., 2015). These cognitive disorders can have
major consequences on patient quality of life, return to work, or
autonomy, and thus represent a major public health issue which
requires investigation.
To identify and characterize subgroups of patients at risk of
cognitive impairment induced by cancer and its treatment, and
to adapt patient treatment, it is essential to discover biological
factors mediating cognitive problems and/or risk factors, such
as genetic polymorphisms, inflammatory indicators, or blood
biomarkers (Kesler et al., 2013; Wang et al., 2015). Some
biomarkers, that are either predictive of risk or produced in
response to treatment or the cancer itself, can be relatively
easily measured by blood sampling before, during, and after
management of the cancer. Such biological predictive factors
may also correlate with cerebral imaging, to provide information
about brain structure and volume changes involved in cognitive
impairment (Wang et al., 2015).
The objective of this review was to establish a summary of
original articles published since 2005, including all biological
predictive factors of cognitive changes in cancer patients,
particularly after cancer treatment. Moreover, we discuss the
Abbreviations:AC/CAF, Cyclophosphamide/cyclophosphamide plus fluorouracil;
ALL, Acute lymphoblastic leukemia; APOE, Apolipoprotein E; Aβ40 and Aβ42,
amyloid-β peptides 40 and 42; CMF, Cyclophosphamide, methotrexate, and
fluorouracil; COMT, Catechol-O-methyltransferase; CRP, C-reactive protein;
CSF, Cerebrospinal fluid; CT, Chemotherapy; DNA, Deoxyribonucleic acid;
Dox, Doxorubicin; ELISA, Enzyme-linked immunosorbent assay; EPO,
Erythropoietin; GnRH, Gonadotropin-releasing hormone; Hb, Hemoglobin;
IL, Interleukin; INFγ, Interferon γ; LPC, Lysophosphatidylcholine; MCP-1,
Monocyte chemoattractant protein 1; MMSE, Mini-mental State Examination;
MTHFR, 5,10-methylenetetrahydrofolate; mRCC, Metastatic renal cell cancer;
pNF-H, Phosphorylated neurofilament subunit H; SM, Sphingomyelin; TNFα,
Tumor necrosis factor-alpha; TNF-RII, Tumor necrosis factor-receptor type II;
VEGF, Vascular endothelial growth factor; VEGFR TKI, Tyrosine kinase VEGF
receptor; RT, Radiotherapy.
limitations of these studies, concerning their different types,
methods, results, and interpretation.
METHODS USED FOR INFORMATION
STRATIFICATION
Articles were retrieved from PubMed using the following key
words:
- MeSH terms: “cognition disorders,” “neurotoxicity
syndromes,” “biological markers,” “prognosis,” “biological
factors”
- PubMed terms: “predictive factors,” “cancer,” “chemobrain,”
“chemofog,” “cognitive dysfunction,” “cognitive impairments”
This review was guided by the PRISMA statement and used
a search strategy focused on three components: “cognition
disorders,” “predictive factors”/”biological markers,” and
“neoplasms,” searched in PubMed (with MeSH and PubMed
terms). Original studies since 2005 were included, regardless
of type (i.e., cross-sectional and longitudinal, randomized, and
non-randomized, single center and multicenter). Selection was
not based on cancer type; mainly acute lymphoblastic leukemia
(ALL), acute myeloid leukemia (AML), myelodysplastic
syndrome (MDS), breast, lung, prostate, and differentiated
thyroid carcinoma were included; however, brain tumors
and cancers involving brain metastasis were excluded,
because of their mass effects and potential consequences of
surgery/resection on the brain, which are likely to directly impact
cognitive function (Table 1). Moreover, all types of cancer
treatments were included, except encephalic radiotherapy,
which can have direct effects on brain function, edema, and
cognition (Table 1). Studies for which predictive factors were
cerebral and/or imaging parameters (magnetic resonance
imaging/hippocampal volume or metabolic activity) or that
did not address one or more of the three components, cancer,
cognition, or biological mechanisms, were also excluded, along
with clinical, physiopathological, and psychological parameters.
Only human studies were included, thus preclinical animal
studies were not taken into account.
The first exclusion criterion, evaluated by reading abstracts,
was the absence of at least one of the three domains, i.e.,
“cognition disorders,” “predictive factors,”/“biological markers,”
and “neoplasms.” Between 2005 and 2015, 65 studies at least
partly covered the topic under investigation. Other exclusion
criteria, determined by reading entire papers, concerned studies
of brain tumors or cranial radiotherapy, or the absence of
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TABLE 1 | Main antitumor treatments and their mechanisms of action reported within the 23 selected publications that can be linked to modified
biological factors and cognitive dysfunctions.
Cancer type Treatment Mechanisms of action
Breast Leuprolide GnRH agonist: reduce estrogen levels by continuous (and not pulsate) infusion of a GnRH action mimic
Tamoxifen Adjuvant hormonal treatment: blockage of estrogenic receptors (ER) in early and advanced ER-positive breast cancers
Exemestane orally active aromatasea inhibitor: irreversible blockade of estrogen production
Anti-aromatases Competition with aromatase which blocks estrogen synthesis (not indicated in cited publications)
Doxorubicin Antibiotic intercalating DNA agent, inhibitor of Topoisomerase II, and oxygen free radical producer leading to toxicity
Cyclophosphamide Bifunctional inhibitor of DNA transcription and replication leading to mitotic cell apoptosis
Docetaxel Cytotoxic properties via inhibition of the microtubule dynamic during mitosis
5-FU Inhibition of thymidylate synthase (inhibition of DNA synthesis)
Vincristine Stop tubulin polymerization and block cell during metaphase
Methotrexate Inhibition of folic acid (cytotoxic effect) through inhibition of mitochondrial metabolism
ALLb Methotrexate Inhibition of folic acid (cytotoxic effect) through inhibition of mitochondrial metabolism
Cytarabine Block DNA synthesis during cell division
mRCCc or GISTd Sunitinib Inhibition of tyrosine kinase receptors involved in tumor growth
Sorafenib Kinase inhibitor which leads decrease of tumor cell proliferation
VEGFR inhibitors Angiogenesis inhibitor (stop tumor growth)
Radiotherapy Tumor cell apoptosis by DNA deterioration
aAromatase, enzyme responsible of the biosynthesis of estrogen.
bALL, Acute lymphoblastic leukemia.
cmRCC, metastatic renal cancer carcinoma.
dGIST, Gastrointestinal solid tumor.
clear data on cognition and/or biomarker levels. Of the initially
selected 65 studies, 23 were finally included in the analysis
(Figure 1). These studies aimed to evaluate and characterize
changes in several biological factors predictive for cognitive
alteration in cancer patients, often in association with treatment.
Different domains of cognition were assessed by batteries of
neuropsychological tests and self-reports of cognitive function.
The biological factors covered in this review are summarized in
Tables 2–6. Most often, blood and serum samples were analyzed
as simple and rapid tests with potential to provide information
about the risk of cancer patients developing cognitive issues,
and to facilitate identification of optimal treatment regimens for
specific patient populations.
BIOLOGICAL MARKERS AND COGNITIVE
IMPAIRMENTS IN TREATED CANCER
PATIENTS
Plasma Biomarkers
Plasma Inflammatory Responses
The main cytokines analyzed in the reviewed studies were the
pro-inflammatory triad, interleukin-6 (IL-6), tumor necrosis
factor-alpha (TNF-α), and interleukin 1β (IL-1β). As IL-6 is an
early mediator of inflammation and a key component of the acute
phase response, it can alsomoderate inflammation by dampening
TNF-α and IL-1β responses. Currently, the exact mechanisms
involved in the inflammatory response during cancer therapy are
not fully understood. Nevertheless, in cancer patients, circulating
levels of cytokines were often increased and could be significant
determinants of the alteration of particular cognitive functions
after chemotherapy (Meyers et al., 2005; Ishikawa et al., 2012;
Cheung et al., 2015). Based on the study by Ishikawa et al. (2012),
it was difficult to conclusively link the observed cognitive issues
with chemotherapy treatment since (i) cytokines, including IL-
6, were measured in patient populations suffering from various
types of advanced and inoperable or recurrent cancers and
(ii) the delay between the end of the treatment and the time
of the plasma assay was not stated. The study conducted by
Meyers demonstrated that at baseline, higher IL-6 levels were
associated with poorer executive functions, confirming that
cancers are associated with high levels of circulating cytokines,
connected with cognitive dysfunction, before chemotherapy. A
longitudinal study by Cheung et al. (2015) established that higher
concentrations of IL-1β and IL-6 were associated with more
severe cognitive disturbance, and that increased IL-1β specifically
was associated with poorer response speed performance during
or just after the end of a chemotherapy treatment episode
(Cheung et al., 2015; Table 2). In contrast, elevated IL-4 levels
were linked to better response speed and fewer cognitive
complaints in patients with breast cancer (Table 2), suggesting
that maintenance of IL-4 levels during cancer care is likely to
be neuroprotective (Cheung et al., 2015). Interestingly, breast
cancer patients treated with chemotherapy had significantly
elevated IL-6 and TNF-α levels after approximately 5 years off-
therapy, compared with healthy controls, with an interaction
between these two cytokines (Kesler et al., 2013). This study was
particularly informative, since it correlated increased cytokine
levels with diminished hippocampal volume, which is associated
with verbal memory function. In agreement, an independent
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FIGURE 1 | PRISMA statement diagram illustrating the process of report identification, information selection and final inclusion for the present
overview. The first exclusion criterion form the reading of the abstract, concerns the absence of the 3 combined domain, i.e., “cognition disorders,” “predictive
Factor”/”biological markers” and “neoplasms.” The second exclusion criterion after reading of the entire papers, concerns brain tumors, cranial radiotherapy or the
absence of clear data on cognition and/or biological marker dosage.
correlation between higher plasma IL-6 levels and deteriorated
memory performance was described in breast cancer patients
exposed to adjuvant local radiotherapy (Table 2; Shibayama et al.,
2014). Together, these data suggest that cancer leads to increased
plasma levels of selected pro-inflammatory cytokines, and that
increased plasma IL-6 levels, likely resulting from chemotherapy
or radiotherapy, may be a key systemic factor involved in, and/or
predictive of, cognitive dysfunction (Table 2).
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Besides IL-6, which was described as marker of both
cancer-associated and cancer treatment-induced inflammation,
studies of other cytokines were less frequently reported.
A longitudinal cross-sectional study, including baseline
measurements, demonstrated changes in a number of pro-
inflammatory cytokines; however, only levels of TNF receptor
type-II (TNF-RII) were significantly higher in plasma from
chemotherapy-treated patients compared with those who did
not receive chemotherapy, with no differences observed in
IL-1ra, IL-6, or C-reactive protein (CRP; Ganz et al., 2013). In
detail, significant correlations between plasma TNF-RII and
self-reported memory complaints, but not cognitive dysfunction
evaluated by neuropsychological tests, was demonstrated
at baseline (associated with relatively diminished brain
metabolism). The study also demonstrated increased TNF-
RII over time in patients who had received radiotherapy (first
end point), different chemotherapy regimens (second end point),
and then endocrine therapy (third endpoint; Table 2), leading
them to hypothesize that fatigue and cognitive complaints may
be caused by disturbances in TNF pathways (Ganz et al., 2013).
In addition to cancer-related increases in circulating
cytokine levels, data reported by Janelsins et al. (2012)
support the idea that some cytokines may be specifically
up-regulated in response to chemotherapy, and contribute to
the development of cognitive difficulties. The study compared
cytokine levels of IL-6, IL-8, and monocyte chemoattractant
protein-1 (MCP-1) in patients receiving doxorubicin (Dox)-
based cyclophosphamide/cyclophosphamide plus fluorouracil
(AC/CAF) or Dox-based cyclophosphamide, methotrexate and
fluorouracil (CMF) chemotherapy. The results demonstrated
augmentation and diminution of cytokine levels in the AC/CAF
and CMF groups, respectively, over time from baseline (prior
to chemotherapy) and after two consecutive chemotherapy
cycles, with a significant difference in levels of IL-6 between the
two groups, suggesting that chemotherapy can induce specific
cytokine changes. However, the study was under-powered
and the time-points for blood sampling (before chemotherapy
cycle) and cognitive evaluation (after chemotherapy cycle)
did not match, hence it is difficult to conclusively evaluate
the link between cytokine/chemokine changes and cognition,
other than the reported negative correlation between MCP-1
and forgetfulness, difficulty with concentration, and thinking
(subjective complaints, Table 2; Janelsins et al., 2012).
Circulating cytokines associated with cognitive impairment in
cancer patients during the course of treatment, or in survivors
after the end of treatment, represented the most measurable
and measured factors, and studies converged to suggest that
chemotherapy could dysregulate cytokine levels, which may
interfere with brain functioning, leading to cognitive impairment
(Ahles and Saykin, 2007). Indeed, some cytokines, including
IL-6, IL-1β, and TNF-α, could have causal roles by crossing
the BBB via active transporters (Cheung et al., 2015) and can
interact with synapses (Wang et al., 2015), thereby leading to
systemic communication between peripheral cytokines and the
brain, rather than central cytokine production. This hypothesis
is supported by a recent study by Hayslip et al. (2015), which
proposed direct intravascular oxidative modification of plasma
proteins by chemotherapy, leading to monocyte release of TNF-α
which, by diffusing through the BBB, could then activate cascades
of events potentially causing cognitive impairment (Hayslip
et al., 2015). They demonstrated that the exogenous anti-oxidant,
sodium-2-mercaptoethane sulfonate (mesna), present only in
blood and urine, reduced plasma protein oxidation and TNF-
α levels in patients receiving Dox-containing chemotherapy
(Hayslip et al., 2015). Also, the observation that changes in
plasma TNF-α levels were linked to reduced left hippocampal
volume in cancer patients receiving chemotherapy (Kesler et al.,
2013), suggests that cerebral apoptosis, or other cell death
mechanisms, are likely responsible for altered verbal memory
performance. Such cell death mechanisms could be counteracted
by neutralization of circulating cytokines.
Although this hypothesis raises interesting therapeutic
options, other studies did not show any significant correlation
between plasma cytokine levels and cognitive impairment with
or without chemotherapy (Pomykala et al., 2013). In fact, co-
variations between metabolism in selected brain regions and
cytokines were detected by comparing values at baseline and
1 year after treatment completion in a group of patients who
received chemotherapy (Pomykala et al., 2013). Overall, there is a
clear difficulty in postulating a direct link between any particular
cytokine that may be specifically up-regulated by a specific
chemotherapy and responsible for a selected type of cognitive
dysfunction. The observed discrepancies between studies may
be due to differences in chemotherapy regimens, time periods
between measurement of cytokine plasma levels and the end
of chemotherapy, measurements of cytokine levels in serum or
plasma, or the variable sensitivities of the methods used for
measurement. Principal tests applied were the enzyme-linked
immunosorbent assay (ELISA), including different variants such
as the high sensitivity multiplex immunoassay (Ganz et al.,
2013; Kesler et al., 2013; Pomykala et al., 2013; Cheung et al.,
2015), or regular and high sensitivity kits (Ganz et al., 2013).
Currently, the detailedmechanisms underlying cognitive changes
remain unclear and future studies are required to obtain more
data about the direct or indirect links between inflammatory
responses and brain disorders associated with cancer therapy.
It will be important to further consider the role of cytokines as
predictive biomarkers for cognitive impairment in cancer and
cancer-treated patients and to propose new cytokine inhibitors
or antagonists as therapeutic options.
Non-inflammatory Biomarkers in Blood and Serum
Samples
Since tumors can expand through development of angiogenic
features and via release of angiogenetic factors, including vascular
endothelial growth factor (VEGF), recently introduced targeted
therapies include inhibitors of tyrosine kinase VEGF receptor
(VEGFR TKI) and drugs targeting VEGF itself. As VEGF is
also involved in neurogenesis and brain vascularization, it might
be supposed that levels of VEGF could be linked to cognitive
impairments (Table 3, Ishikawa et al., 2012). Accordingly, its
levels were determined in a cross-sectional study of metastatic
renal cancer (mRCC) patients treated with VEGFR TKI (8 week
treatment period). The patients exhibited elevated erythrocyte
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sedimentation rates (ERS), CRP levels, and neutrophil counts,
that were negatively correlated with learning, memory, attention,
concentration, and executive functions (Mulder et al., 2014);
however, no correlations were found with cytokine, hemoglobin
(Hb), or electrolyte levels, leucocyte counts, or VEGF levels
in blood samples. In a more recent longitudinal study, 30%
of mRCC patients treated with anti-angiogenics were found to
develop fatigue and cognitive disorders, while VEGF plasma
levels measured at baseline, and 3 and 6 months from baseline,
were associated with fatigue, but not with cognitive dysfunction
(Joly et al., 2016). The impact of TKI, and of cancer itself, should
be investigated further to clarify the exact effects of TKI on
inflammatory responses and other circulating plasma markers,
such as Hb, detrimental to cognitive performance.
Several studies investigating the contribution of
chemotherapy-induced anemia to cognitive impairment in
cancer patients suggested that changes in Hb were linked to the
development of cognitive impairment during chemotherapy.
This was stressed in the elderly cancer population studied
by Mancuso et al. (2006), were Hb levels were associated
with quality of life, functional capacity, mental decline, and
depression, suggesting that maintenance of normal Hb levels
is essential to prevent cognitive decline during chemotherapy.
Low powered studies on treatments with specific therapies, such
as recombinant human erythropoietin (rHuEPO), led to show
improved Hb levels which were correlated with better cognitive
function (Table 3; Mancuso et al., 2006; Massa et al., 2006).
When rHuEPO is administered several times each week, it can
compensate for cancer and chemotherapy-induced anemia after
approximately 3 weeks of chemotherapy. In a larger cohort
study, Iconomou et al. (2008) observed no significant changes in
cognitive function in responders, exhibiting increased Hb levels
after 12 weeks of rHuEPO treatment, despite improvement of
physical function and diminished fatigue (Iconomou et al., 2008).
In contrast, other studies using the same types of cognitive tests
failed to detect evidence for a protective effect of erythropoietin
(EPO) against delayed cognitive dysfunction (24 months from
the end of the treatment) in groups of patients with breast cancer
receiving chemotherapy (Fan et al., 2009; Table 3).
Other systemic biological markers were also highlighted. A
relationship between androgen receptors and amyloid precursors
has been described (Takayama et al., 2009). Increased levels of
amyloid-β40 (Aβ40), a marker associated with the Alzheimer
disease, did not appear to be associated with cognitive mini-
mental state examination (MMSE) scores after leuprolide
treatment in prostate cancer patients (Tan et al., 2013). However,
this study had some limitations, including a lack of evaluation
of the ratio Aβ40/Aβ42 in plasma, indicating that the interesting
hypothesis of a possible impact of cancer treatment on Aβ plasma
levels and cognition deserves further investigation (Table 3).
Another candidate plasma marker for cognitive
dysfunction following therapy-induced brain damage is
axonal phosphorylated neurofilament subunit H (pNF-H), levels
of which are increased in the blood of patients who have had
acute brain ischemic stroke compared with controls, and are
associated with the severity of the stroke (Singh et al., 2011;
Andreano et al., 2012). Thus, Natori et al. (2015) considered
that pNF-H would constitute an interesting systemic biomarker
of neuronal lesions and measured its levels in the serum of
breast cancer patients at baseline, after one to seven cycles of
different chemotherapy regimens, and 1 month–1 year after the
end of therapy. They established that pNF-H levels increased
with the number of chemotherapy doses administered, but did
not find any correlation with neuropsychological scores (Natori
et al., 2015; Table 4). This suggests that measurement of serum
pNF-H in chemotherapy-treated cancer patients, alongside the
application of more sensitive batteries of cognitive tests, may be
worthwhile to further evaluate pNF-H as a biomarker of neural
axonal damage and cognitive impairment.
Hormonal Factors
Endocrine function, specifically gonadal and stress hormones,
may also contribute to cognitive difficulties during cancer
treatment. To date, the results of research into hormonal
factors remain inconclusive, and studies are often related to
patients receiving hormonal therapy. For example, significant
reductions in free testosterone and β-estradiol levels were
detected in prostate cancer patients after 3 months exposure
to leuprolide, and some changes in spatial memory also were
observed during treatment; however, there was no association
between the changes in hormonal factors and those in cognition
(Jenkins et al., 2005; Table 5). When therapy to suppress thyroid-
stimulating hormone (TSH) was administered to patients with
differentiated thyroid carcinoma, a positive correlation between
free serum T4 levels and cognitive processing speed was
detected (Moon et al., 2014), suggesting that exogenous T4
supplementation can improve cognitive function in this group
of patients. In addition, given that gonadal hormonal levels
can influence the hypothalamic-pituitary-adrenal axis (HPA), the
cognitive and endocrine effects of the cortisol activating stressor,
cold pressor stress (CPS), were tested in breast cancer patients
previously treated with chemotherapy, and then receiving
Lupron (Andreano et al., 2012). The glucocorticoid (cortisol)
response to CPS was absent in the cancer patient group compared
with controls, and delayed recall performance was also impaired
in the individuals with cancer (Andreano et al., 2012). Thus,
stress-induced cortisol favoring memory consolidation can be
selectively altered in cancer patients. Other than this interesting
study relating regulation of the HPA axis to cognitive impairment
in cancer patients, there is little evidence to link the role of
chemotherapy, stress, and/or cancer on circulating hormone
levels and cognition.
Genetic Factors
There is relative heterogeneity among cancer patients regarding
(i) the various domains of cognition that can be affected,
including working memory, executive functions, verbal memory,
and processing speed; and (ii) the proportion of patients
exhibiting long-term cognitive deficits, independent of fatigue or
emotional disturbances. This has prompted medical researchers
to investigate potential predisposing factors for the development
of cognitive impairment during cancer and its treatment. Indeed,
immune status, cancer diagnosis in the elderly, and/or a number
of key genetic polymorphisms can predispose to cognitive
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changes (Ahles and Saykin, 2007; Mandelblatt et al., 2013;
Janelsins et al., 2014). Should studies clearly demonstrate genetic
predisposition, this could enable adaption of treatment to specific
patient populations. Accordingly, recent studies have shown
that genetic factors may be linked to cognitive impairments in
cancer patients after therapy; for example, the gene encoding
apolipoprotein E (APOE), located in chromosome 19, which
functions in lipid transport and regulation of inflammation.
APOE has three allelic variants (E2, E3, and E4), which include
various combinations of two single nucleotide polymorphisms,
rs7412 and rs429358. Chemotherapy-treated breast cancer
patients carrying APOE-4 allele E4, a well-known risk factor
for Alzheimer’s disease (Ahles, 2012), have a higher risk of
cognitive dysfunction during the course of cancer treatment
(Mandelblatt et al., 2013). Consistent with these findings,
Krull et al. analyzed various polymorphisms among childhood
ALL survivors, and identified three that were associated
with neurocognitive disorders, such as attentiveness, response
speed, or parent-reported attention problems. In particular, an
association between APOE-4 and attention deficit was described
in survivors (Table 5). This study also identified associations
between a single nucleotide polymorphism in the genes
encoding methionine synthase (MS), which is responsible for
the conversion of homocysteine to methionine, and monoamine
oxidase A (MAOA), which catalyzes the deamination of amines
such as dopamine, serotonin, or norepinephrine, and attention
difficulties (Krull et al., 2013a).
The key role of neurotransmitters as potential predisposing
markers, is stressed by the other polymorphism commonly
reported as linked to cognitive impairments, the Val158
Met encoding single-nucleotide polymorphism in catechol-
O-methyltransferase (COMT), which catalyzes the metabolic
breakdown of catecholamines through the methylation of
dopamine and noradrenaline (Ahles and Saykin, 2007). In
detail, codon 158 of COMT on chromosome 22q11, can encode
for either a valine or a methionine residue (Small et al.,
2011). The valine-containing variant protein exhibits elevated
activity, leading to enhanced neurotransmitter degradation
and consequent diminished neurotransmission (Table 5). This
polymorphism predisposed a subgroup of patients with breast
cancer to a higher risk of diminished cognitive performance,
including attention, verbal fluency, and motor speed, evaluated
6 months after the end of chemotherapy (Small et al., 2011).
Other genetic polymorphisms also appear to be implicated
in cognitive changes, such as those regulating folate pathways.
Kamdar et al. (2011) investigated six different polymorphisms in
genes involved in the folate pathway in childhood ALL survivors
(Kamdar et al., 2011; Table 5), and described two genotypes
in genes encoding 10-methylenetetrahydrofolate reductase and
sphingomyelin (SM) as significantly correlated with general
neurocognitive impairment (Kamdar et al., 2011).
Biological Factors in Cerebrospinal Fluid
When attempting to identify direct biological factors associated
with cognitive alterations in cancer patients, variations in
levels detected in cerebrospinal fluid (CSF) would be expected
to provide better information about causal links with, or
consequences of, treatment. Relationships between alterations
in phospholipids, SM, and lysophosphatidylcholine (LPC)
concentrations, as markers of white matter integrity, and some
domains of cognitive function, were identified in children
with ALL before and during long periods of chemotherapy
(methotrexate administration over a period of years; Krull
et al., 2013b). SM and LPC were shown to increase in CSF
following chemotherapy induction and were associated with
motor speed or visual working memory, and verbal working
memory, respectively (Table 6; Krull et al., 2013b). These data
indicate the occurrence of early cerebral neurochemical and
neurocognitive alterations during chemotherapy, suggesting
that, in addition to the effects of cancer itself, there is a direct
and rapid impact of chemotherapy on the brain (white matter),
and that brain imaging of the white matter may be beneficial
during methotrexate administration. Methotrexate alters
mitochondrial oxidative metabolism by inhibiting recycling of
nicotinamide adenine dinucleotide, leading to accumulation of
monounsaturated fatty acids. Thus, Moore et al. (2008) evaluated
fatty acid levels (ratio between monounsaturated/saturated)
in the CSF of patients with childhood ALL treated with
methotrexate for more than 3 years (Moore et al., 2008). The
number of intrathecal methotrexate doses received during
the first year was significantly correlated with an increase in
the stearic/oleic acid ratio, which was negatively correlated
with decreased global intelligence and academic mathematics
ability, while the palmitic/palmitoleic acid ratio was negatively
correlated with global intelligence alone (Table 6; Moore et al.,
2008). Hence, these two studies strongly support a specific
deleterious impact of chemotherapy on beta-oxidation and fatty
acid metabolism in the brain, suggesting that membrane and
myelin defects may accompany cognitive dysfunction in some
populations of cancer patients.
CSF analysis can also provide inform about the microtubule-
associated protein tau, whose CSF levels have already
been associated with neurotoxicity and neurodegenerative
pathologies. There is a significant increase in tau protein after
induction and during consolidation, compared with at the time
of diagnosis, in ALL patients. The level of tau measured before
maintenance therapy was negatively correlated with verbal
abilities (Protas et al., 2009), suggesting probable neural cell
injury.
Overall, studies of patients with ALL receiving methotrexate-
containing chemotherapy regimens for long periods demonstrate
robust links between cognitive domains, such as working
memory or verbal abilities, and modified CSF components, such
as fatty acids, phospholipids, and even tau protein, which plays
an important role in Alzheimer’s disease (Table 6). Although
the sampling method to obtain CSF by lumbar puncture is
more invasive than blood tests, it appears to provide promising
predictive biological information relating to cognitive function in
cancer patients, which could be highly useful in various settings.
Co-Morbidities and Limitations
It is important to consider clinical, physiopathological, and
psychological factors in addition to biological markers, in
relation to cognitive impairment of patients with cancer. In
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particular, to evaluate the contribution of co-morbidities and
associated treatments, is essential to understand patient history
and knowledge of these factors can help to predict cognitive
impairments and determine the significance of changes in
circulating factors in cancer patients during treatment. In
support of this idea, in a study aiming to identify predictors
of cognitive performance in breast cancer patients, treatment
for hypertension was identified as having a significant negative
impact on verbal fluency and working memory performance,
and treatment for diabetes mellitus, was found to detrimentally
affect executive functioning and reaction speed (Schilder et al.,
2010). The same study also demonstrated that a higher number
of “reproductive years” (as an indicator of lifetime estrogen
exposure) appears to predict worse executive functioning. A
longitudinal cohort study by Bender et al. (2013) demonstrated
that before adjuvant chemotherapy, post-menopausal breast
cancer patients exhibit poorer cognitive function than matched
healthy controls; however, factors related to oral contraception
were better predictors of verbal memory and attention in both
controls and cancer patients (Bender et al., 2013), likely due
to the positive biological impact of estrogen on brain function.
The roles of various other factors, such as surgery, sleep
disorders, anxiety, and cancer itself, on cognitive impairments
specifically observed in cancer patients before chemotherapy,
remain unknown. More generally, a study by Mandelblatt et al.
(2014) revealed that elderly breast cancer patients with more
advanced cancer or high levels of co-morbidity (including
diabetes and cardiovascular disease) had higher rates of cognitive
impairment than those with low co-morbidity levels, unlike
matched control groups (Mandelblatt et al., 2014). These results
highlight that some cancer patient populations are at risk of
developing cognitive deficits as a result of cancer management,
including chemotherapy.
Several limitations should be noted in the studies analyzed
in this report. There is an absence of meta-analyses, and the
majority of available studies were prospective cross-sectional
trials, mostly composed of small samples, and consequently
had relatively low statistical power. Also, the studies included
are not strictly comparable, because of the different methods
used. Biological measurement methods are the main limit, and
thus the variability in assessed cognitive domains and tests
analyzed should also be considered in evaluation of this review.
Indeed, some studies use global efficiency analyses, such as
MMSE, whereas others applied batteries of tests, which are more
sensitive for objective measurement of cognitive impairments. It
should also be noted that practice effects can modify test results,
particularly in longitudinal studies repeatedly using the same
tests on patients after short periods of time. Finally, the large
diversity of chemotherapy regimens used, inconsistent sampling
points, and various cognitive assessment methods remain the
major obstacles to identification of clear correlations between
circulating biological factors levels and performance in specific
domains of cognition. In addition, brain imaging could be
an interesting approach to correlation of brain activity and
biological markers in patients exhibiting no obvious cognitive
impairment (Ferguson et al., 2007).
CONCLUSION
A number of potential predictive markers have been identified
that require validation in large series. Indeed, initial studies of
factors, such as selected cytokines, stress hormones, CSF proteins,
lipids, or Hb levels, have provided interesting information
about changes in biomarkers that evolve during the course
of the treatment of cancer patients, and also about genetic
polymorphisms predisposing to cognitive deficits. Additional
longitudinal studies, and investigation of other factors, previously
identified in different pathological situations as associated with
fatigue or aging, should facilitate better characterization of risk of
cognitive impairment in cancer.
The question addressed in this study is among the priorities in
cancer patient care and the ability to use biological risk factors to
predict, better understand, and help to prevent cognitive issues,
or adjust treatments for specific populations of patients identified
as at risk, would be of major benefit. Such markers would
also likely facilitate identification of biological mechanisms
underlying neurotoxicity, and could open new avenues for
testing and evaluation of therapeutic strategies designed to
prevent cognitive dysfunction during cancer treatment, leading
to improved quality of life, autonomy, and return to work rates
of cancer survivors.
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